Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER) and progesterone receptor (PR), as well as no over-expression of human epidermal growth factor receptor 2 (HER2), and is an aggressive subtype comprising 10–20% of breast cancer incidences1–3. Here, ESR1 is linked to triple-negative breast carcinoma.